AstraZeneca Reaffirmed as Buy by UBS, Target at £14,200

UBS reaffirms Buy rating on AstraZeneca with a p14,200.00 price target. Analyst Matthew Weston has a 4-star rating and a 64.10% success rate. The current analyst consensus is a Strong Buy with an average price target of p13,531.92, a 20.61% upside from current levels.

UBS has reaffirmed its Buy rating on AstraZeneca (NASDAQ: AZN) with a price target of $142.00, as announced by analyst Matthew Weston. Weston, who has a 4-star rating and a 64.10% success rate, believes that the stock offers significant upside potential. The current analyst consensus is a Strong Buy, with an average price target of $135.31.92, indicating a 20.61% upside from current levels.

AstraZeneca reported earnings of $1.09 per share for the quarter, meeting analysts' expectations and surpassing revenue estimates of $14.08 billion. The company's net margin stood at 14.14%, with a year-over-year revenue increase of 16.1%. AstraZeneca also announced a semi-annual dividend of $0.505, reflecting a yield of 2% and a payout ratio of 82.73% [1].

The stock has seen increased interest from institutional investors, with 594 adding shares to their portfolios in the most recent quarter, compared to 522 decreasing their positions. Notable recent moves include Fisher Asset Management, LLC adding 9.2 million shares and Bank of America Corp /DE/ adding 7.8 million shares in the first quarter of 2025 [2].

Analysts have also been bullish on AstraZeneca, with 1 firm issuing a Buy rating and none issuing a Sell rating. UBS's Weston has a 4-star rating and a 64.10% success rate, indicating a strong track record. The current analyst consensus is a Strong Buy, with an average price target of $135.31.92, suggesting a 20.61% upside from current levels [2].

While AstraZeneca has shown strong financial performance and has received positive analyst ratings, investors should remain vigilant about potential risks, such as pricing challenges and trade uncertainties. The company's recent earnings report and analyst ratings provide a positive outlook for AstraZeneca's stock, but investors should conduct their own due diligence before making investment decisions.

References:
[1] https://www.marketbeat.com/instant-alerts/astrazeneca-nasdaqazn-announces-quarterly-earnings-results-hits-expectations-2025-07-30/
[2] https://www.quiverquant.com/news/AstraZeneca+Stock+%28AZN%29+Opinions+on+Record+Quarterly+Earnings